Oxford University’s welcome announcement of the efficacy of its COVID-19 vaccine trial brings to three – along with Pfizer/BioNTech and Moderna – the number of promising vaccines for halting the pandemic. Doubtless more will follow. But even when production and distribution are underway, limited supply will be prioritised in protecting the population of our planet. Where do efficacy and equity meet?
OPGDI is proud to publish Professor Robert Walker’s response to this immediate urgent question, in his paper, “Who should receive the Covid-19 vaccine first?” This paper expands upon the dialogue of OPGDI’s inaugural “COVID-19 In-Conversation” event, an online seminar jointly hosted with Beijing Normal University on 23rd October 2020.
